India, May 22 -- AstraZeneca PLC (AZN), a biopharmaceutical company, and Daiichi Sankyo Company Limited (4568.T), a healthcare company, on Friday announced the approval of Datroway in the treatment of metastatic triple-negative breast cancer by the U.S. Food and Drug Administration (FDA).
Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers diagnosed, with 345,000 new cases recorded globally every year. Named for the absence of the usual biomarkers of breast cancer - estrogen receptors, progesterone receptors, and HER2- overexpression- the disease shows an overall survival (OS) of 12-18 months. The cancer is diagnosed with the detection of the TROP2 protein in tumors.
Datroway (datopotamab deruxtecan) is a TROP2-tar...